Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6

Biological Psychiatry

Volumn 83, Issue 5, 2018, Pages 428-437

  Zhu, Kaichuan ^a,b,d   Xiang, Xianyuan ^b   Filser, Severin ^a,b,d   Marinković, Petar ^a   Dorostkar, Mario M ^a,b,d   Crux, Sophie ^a,b,d   Neumann, Ulf ^g   Shimshek, Derya R ^g   Rammes, Gerhard ^e   Haass, Christian ^a,c,d   Lichtenthaler, Stefan F ^a,d,e,f   Gunnersen, Jenny M ^h   Herms, Jochen ^a,b,d  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Protein Analysis Unit   (Germany)

^d Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; BACE1 inhibition; Dendritic spines; In vivo two photon imaging; Long term potentiation; Sez6

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE INHIBITOR; BRAIN ENZYME; MEMBRANE PROTEIN; NB 360; SEIZURE PROTEIN 6; TAMOXIFEN; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; NERVE PROTEIN; SECRETASE; SEZ6 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; DENDRITIC SPINE; ELECTROPHYSIOLOGICAL PROCEDURES; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL SLICE; IMMUNOBLOTTING; INTRAVITAL MICROSCOPY; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; HIPPOCAMPUS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DENDRITIC SPINES; HIPPOCAMPUS; LONG-TERM POTENTIATION; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY;

EID: 85010206570     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.12.023     Document Type: Article

References (63)

1. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
2. Selkoe, D.J., Hardy, J., The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8 (2016), 595–608.
3. 42 fibrils. Science 293 (2001), 1491–1495.
4. Vassar, R., BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimer's Res Ther 6 (2014), 1–14.
5. Barão, S., Moechars, D., Lichtenthaler, S.F., De Strooper, B., BACE1 physiological functions may limit its use as therapeutic target for Alzheimer's disease. Trends Neurosci 39 (2016), 158–169.
6. Kennedy, M.E., Stamford, A.W., Chen, X., Cox, K., Cumming, J.N., Dockendorf, M.F., et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Sci Transl Med, 8, 2016, 363ra150.
7. Dominguez, D., Tournoy, J., Hartmann, D., Huth, T., Cryns, K., Deforce, S., et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280 (2005), 30797–30806.
8. Willem, M., Garratt, A.N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 (2006), 664–666.
9. Savonenko, A.V., Melnikova, T., Laird, F.M., Stewart, K.-A., Price, D.L., Wong, P.C., Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 105 (2008), 5585–5590.
10. Filser, S., Ovsepian, S.V., Masana, M., Blazquez-Llorca, L., Brandt Elvang, A., Volbracht, C., et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry 77 (2015), 729–739.
11. DeKosky, S.T., Scheff, S.W., Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27 (1990), 457–464.
12. Bittner, T., Burgold, S., Dorostkar, M.M., Fuhrmann, M., Wegenast-Braun, B.M., Schmidt, B., et al. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol 124 (2012), 797–807.
13. Shimizu-Nishikawa, K., Kajiwara, K., Sugaya, E., Cloning and characterization of seizure-related gene, SEZ-6. Biochem Biophys Res Commun 216 (1995), 382–389.
14. Shimizu-Nishikawa, K., Kajiwara, K., Kimura, M., Katsuki, M., Sugaya, E., Cloning and expression of SEZ-6, a brain-specific and seizure-related cDNA. Brain Res Mol Brain Res 28 (1995), 201–210.
15. Kuhn, P.H., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J 31 (2012), 3157–3168.
16. Pigoni, M., Wanngren, J., Kuhn, P.-H., Munro, K.M., Gunnersen, J.M., Takeshima, H., et al. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol Neurodegener, 11, 2016, 67.
17. Gunnersen, J.M., Kim, M.H., Fuller, S.J., De Silva, M., Britto, J.M., Hammond, V.E., et al. Sez-6 proteins affect dendritic arborization patterns and excitability of cortical pyramidal neurons. Neuron 56 (2007), 621–639.
18. Mitsui, S., Hidaka, C., Furihata, M., Osako, Y., Yuri, K., A mental retardation gene, motopsin/prss12, modulates cell morphology by interaction with seizure-related gene 6. Biochem Biophys Res Commun 436 (2013), 638–644.
19. Carrodus, N.L., Teng, K.S.-L., Munro, K.M., Kennedy, M.J., Gunnersen, J.M., Differential labeling of cell-surface and internalized proteins after antibody feeding of live cultured neurons. J Vis Exp, 84, 2014, e51139.
20. Cheret, C., Willem, M., Fricker, F.R., Wende, H., Wulf-Goldenberg, A., Tahirovic, S., et al. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J 32 (2013), 2015–2028.
21. Gilissen, C., Hehir-Kwa, J.Y., Thung, D.T., van de Vorst, M., van Bon, B.W.M., Willemsen, M.H., et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 511 (2014), 344–347.
22. Ambalavanan, A., Girard, S.L., Ahn, K., Zhou, S., Dionne-Laporte, A., Spiegelman, D., et al. De novo variants in sporadic cases of childhood onset schizophrenia. Eur J Hum Genet 24 (2016), 944–948.
23. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., Wong, P.C., BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat Neurosci 4 (2001), 233–234.
24. Young, P., Qiu, L., Wang, D., Zhao, S., Gross, J., Feng, G., Single-neuron labeling with inducible Cre-mediated knockout in transgenic mice. Nat Neurosci 11 (2008), 721–728.
25. Feng, G., Mellor, R.H., Bernstein, M., Keller-Peck, C., Nguyen, Q.T., Wallace, M., et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28 (2000), 41–51.
26. Neumann, U., Rueeger, H., Machauer, R., Veenstra, S.J., Lueoend, R.M., Tintelnot-Blomley, M., et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice. Mol Neurodegener, 10, 2015, 44.
27. Ochs, S.M., Dorostkar, M.M., Aramuni, G., Schön, C., Filser, S., Pöschl, J., et al. Loss of neuronal GSK3β reduces dendritic spine stability and attenuates excitatory synaptic transmission via β-catenin. Mol Psychiatry 20 (2015), 482–489.
28. Rochin, L., Hurbain, I., Serneels, L., Fort, C., Watt, B., Leblanc, P., et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A 110 (2013), 10658–10663.
29. Shimshek, D.R., Jacobson, L.H., Kolly, C., Zamurovic, N., Balavenkatraman, K.K., Morawiec, L., et al. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice. Sci Rep, 6, 2016, 21917.
30. Yuan, J., Venkatraman, S., Zheng, Y., McKeever, B.M., Dillard, L.W., Singh, S.B., Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease. J Med Chem 56 (2013), 4156–4180.
31. Huang, Y., Mucke, L., Alzheimer mechanisms and therapeutic strategies. Cell 148 (2012), 1204–1222.
32. Ryan, T.M., Roberts, B.R., McColl, G., Hare, D.J., Doble, P.A., Li, Q.-X., et al. Stabilization of nontoxic Aβ-oligomers: Insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease. J Neurosci 35 (2015), 2871–2884.
33. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 311–321.
34. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
35. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P.H., Williams, L., Maier, M., et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537 (2016), 50–56.
36. Sinha, S., Lieberburg, I., Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci U S A 96 (1999), 11049–11053.
37. Stamford, A.W., Scott, J.D., Li, S.W., Babu, S., Tadesse, D., Hunter, R., et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett 3 (2012), 897–902.
38. May, P.C., Dean, R.A., Lowe, S.L., Martenyi, F., Sheehan, S.M., Boggs, L.N., et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 31 (2011), 16507–16516.
39. Kimura, R., Devi, L., Ohno, M., Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice. J Neurochem 113 (2010), 248–261.
40. Sadleir, K.R., Eimer, W.A., Cole, S.L., Vassar, R., Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol Neurodegener, 10, 2015, 1.
41. Ohno, M., Cole, S.L., Yasvoina, M., Zhao, J., Citron, M., Berry, R., et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 26 (2007), 134–145.
42. De Strooper, B., Lessons from a failed γ-secretase Alzheimer trial. Cell 159 (2014), 721–726.
43. Bittner, T., Fuhrmann, M., Burgold, S., Jung, C.K., Volbracht, C., Steiner, H., et al. γ-Secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci 29 (2009), 10405–10409.
44. Laird, F.M., Cai, H., Savonenko, A.V., Farah, M.H., He, K., Melnikova, T., et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25 (2005), 11693–11709.
45. May, P.C., Dean, R.A., Lowe, S.L., Martenyi, F., Sheehan, S.M., Boggs, L.N., et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31 (2011), 16507–16516.
46. Killick, R., Hardy, J., Simons, J.P., Reducing β-amyloid by inhibition of BACE1: How low should you go?. Biol Psychiatry 77 (2015), 683–684.
47. Zuo, Y., Lin, A., Chang, P., Gan, W.B., Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron 46 (2005), 181–189.
48. Grutzendler, J., Kasthuri, N., Gan, W.-B., Long-term dendritic spine stability in the adult cortex. Nature 420 (2002), 812–816.
49. Nägerl, U.V., Eberhorn, N., Cambridge, S.B., Bonhoeffer, T., Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron 44 (2004), 759–767.
50. Nägerl, U.V., Köstinger, G., Anderson, J.C., Martin, K.A.C., Bonhoeffer, T., Protracted synaptogenesis after activity-dependent spinogenesis in hippocampal neurons. J Neurosci 27 (2007), 8149–8156.
51. Havik, B., Rokke, H., Dagyte, G., Stavrum, A.-K.K., Bramham, C.R.R., Steen, V.M.M., et al. Synaptic activity-induced global gene expression patterns in the dentate gyrus of adult behaving rats: Induction of immunity-linked genes. Neuroscience 148 (2007), 925–936.
52. Kandalepas, P.C., Sadleir, K.R., Eimer, W.A., Zhao, J., Nicholson, D.A., Vassar, R., The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol 126 (2013), 329–352.
53. Hitt, B., Riordan, S.M., Kukreja, L., Eimer, W.A., Rajapaksha, T.W., Vassar, R., β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem 287 (2012), 38408–38425.
54. Wang, H., Song, L., Laird, F., Wong, P.C., Lee, H.K., BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci 28 (2008), 8677–8681.
55. Wang, H., Megill, A., Wong, P.C., Kirkwood, A., Lee, H.-K., Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice. PLoS One, 9, 2014, e92279.
56. Willem, M., Tahirovic, S., Busche, M.A., Ovsepian, S.V., Chafai, M., Kootar, S., et al. η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526 (2015), 443–447.
57. Fol, R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S.W., Roederer, J.-P., et al. Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer's disease mouse model. Acta Neuropathol 131 (2016), 247–266.
58. Ben Halima, S., Mishra, S., Raja, K.M.P., Willem, M., Baici, A., Simons, K., et al. Specific inhibition of β-secretase processing of the Alzheimer disease amyloid precursor protein. Cell Rep 14 (2016), 2127–2141.
59. Miyazaki, T., Hashimoto, K., Uda, A., Sakagami, H., Nakamura, Y., Saito, S.Y., et al. Disturbance of cerebellar synaptic maturation in mutant mice lacking BSRPs, a novel brain-specific receptor-like protein family. FEBS Lett 580 (2006), 4057–4064.
60. Kerr, M.L., Small, D.H., Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: Function, regulation of proteolysis, and implications for drug development. J Neurosci Res 80 (2005), 151–159.
61. Rajendran, L., Honsho, M., Zahn, T.R., Keller, P., Geiger, K.D., Verkade, P., Simons, K., Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 103 (2006), 11172–11177.
62. Maccarrone, G., Ditzen, C., Yassouridis, A., Rewerts, C., Uhr, M., Uhlen, M., et al. Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. J Psychiatr Res 47 (2013), 1572–1580.
63. Khoonsari, P.E., Häggmark, A., Lönnberg, M., Mikus, M., Kilander, L., Lannfelt, L., et al. Analysis of the cerebrospinal fluid proteome in Alzheimer's disease. PLoS One, 11, 2016, e0150672.